Scientific publications

Phase I/II study of weekly PM00104 (Zalypsis® ) in patients with relapsed/refractory multiple myeloma

Ocio EM(1), Oriol A(2), Bladé J(3), Teruel AI(4), Martín J(5), de la Rubia J(6), Gutiérrez NC(7), Rodríguez Díaz-Pavón J(8), Martínez González S(8), Coronado C(8), Fernández-García EM(8), Siguero Gómez M(8), Fernández-Teruel C(8), San Miguel J(9).

(1) Hospital Universitario de Salamanca, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain.
(2) Hospital Universitario Germans Trias I Pujol, Badalona, Spain.
(3) Hospital Clínico de Barcelona, Institut d'Investigacions Biomediques Auguust Pi I Sunyer, Barcelona, Spain.
(4) Hospital Clínico Universitario de Valencia, Valencia, Spain.
(5) Hospital Universitario Virgen del Rocío, Sevilla, Spain.
(6) Hospital Dr. Peset and Universidad Católica San Vicente Mártir, Valencia, Spain.
(7) Hospital Universitario de Salamanca, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain.
(8) PharmaMar, Clinical R&D, Colmenar Viejo, Madrid, Spain.
(9) Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas (CIMA), IDISNA, Pamplona, Spain.

Magazine: British Journal of Haematology

Date: Jun 2, 2015

Haematology and Hameotherapy

Despite improvements in the prognosis of multiple myeloma (MM) associated with the recent introduction of immunomodulatory drugs (IMIDs), such as thalidomide or lenalidomide, and proteasome inhibitors (PIs), such as bortezomib (Richardson et al, 2003; Dimopoulos et al, 2007), MM remains incurable and virtually all patients relapse. Moreover, patients with relapsed MM refractory to lenalidomide and bortezomib have a dismal prognosis (Kumar et al, 2012) and drugs with different mechanisms of action are currently under investigation (Ocio et al, 2014) for these patients.

PM00104 (Zalypsis®) gives rise to double-strand DNA breaks, increases the G0–G1 phase and induces apoptosis (Ocio et al, 2009) in MM cells. It is effective on cell lines resistant to conventional anti-myeloma treatments and it has shown synergy with several anti-myeloma drugs (Ocio et al, 2009, 2010). A previous phase I trial of PM00104 administered as a 1-h intravenous (i.v.) infusion on Days 1, 8 and 15, every 4 weeks established 2·0 mg/m2 as the recommended dose (RD) in patients with solid tumours (Massard et al, 2013).

The evaluation of this schedule, as well as the optimization of the dose of PM00104 in relapsed/refractory MM, was the main objective of the current trial.

CITATION  Br J Haematol. 2015 Jun 2. doi: 10.1111/bjh.13515.

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra